Nathalie Scholler
Penn Ovarian Cancer Research Center,
Center for Research on Reproduction and Womans Health,
Department of Obstetrics and Gynecology,
Penn Ovarian Cancer Research Center, Center for Research on Reproduction and Womans Health, Department of Obstetrics and Gynecology
University of Pennsylvania-School of Medicine
Nathalie Scholler has not added Biography.
If you are Nathalie Scholler and would like to personalize this page please email our Author Liaison for assistance.
Cutting edge: CD83 regulates the development of cellular immunity.
Journal of immunology (Baltimore, Md. : 1950) Mar, 2002 | Pubmed ID: 11884422
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
Molecular cancer therapeutics Oct, 2003 | Pubmed ID: 14578464
Bead-based ELISA for validation of ovarian cancer early detection markers.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2006 | Pubmed ID: 16609024
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Cancer letters Mar, 2007 | Pubmed ID: 16677756
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.
Journal of immunological methods Dec, 2006 | Pubmed ID: 17113097
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.
Cancer letters Oct, 2007 | Pubmed ID: 17560019
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2008 | Pubmed ID: 18451228
A mouse to human search for plasma proteome changes associated with pancreatic tumor development.
PLoS medicine Jun, 2008 | Pubmed ID: 18547137
Systematic evaluation of candidate blood markers for detecting ovarian cancer.
PloS one , 2008 | Pubmed ID: 18612378
Combining a symptoms index with CA 125 to improve detection of ovarian cancer.
Cancer Aug, 2008 | Pubmed ID: 18615684
Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.
Journal of translational medicine , 2008 | Pubmed ID: 18652693
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Sep, 2008 | Pubmed ID: 18768519
Maternal mortality from systemic illness: unraveling the contribution of the immune response.
American journal of obstetrics and gynecology Apr, 2009 | Pubmed ID: 19318152
Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA.
IDrugs : the investigational drugs journal Apr, 2009 | Pubmed ID: 19350459
Use of high density antibody arrays to validate and discover cancer serum biomarkers.
Molecular oncology Dec, 2007 | Pubmed ID: 19383305
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology May, 2009 | Pubmed ID: 19423517
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?
Biomarkers in medicine Jun, 2009 | Pubmed ID: 19684876
Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.
Langmuir : the ACS journal of surfaces and colloids Dec, 2009 | Pubmed ID: 19928944
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
Gynecologic oncology Mar, 2010 | Pubmed ID: 19945742
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Journal of the National Cancer Institute Jan, 2010 | Pubmed ID: 20042715
CA125 in ovarian cancer.
Biomarkers in medicine Dec, 2007 | Pubmed ID: 20477371
Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.
Journal of immunological methods Jan, 2011 | Pubmed ID: 20837020
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
Cancer prevention research (Philadelphia, Pa.) Mar, 2011 | Pubmed ID: 21372036
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
Cancer prevention research (Philadelphia, Pa.) Mar, 2011 | Pubmed ID: 21372037
Novel surface targets and serum biomarkers from the ovarian cancer vasculature.
Cancer biology & therapy Aug, 2011 | Pubmed ID: 21617380
Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
Journal of the National Cancer Institute Nov, 2011 | Pubmed ID: 21917606
Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.
Gynecologic oncology Feb, 2012 | Pubmed ID: 22037318
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor.
Molecular therapy : the journal of the American Society of Gene Therapy Nov, 2011 | Pubmed ID: 22127019
Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.
PloS one , 2011 | Pubmed ID: 22163010
Oncology biomarkers for gynecologic malignancies.
Frontiers in bioscience (Elite edition) , 2012 | Pubmed ID: 22201939
A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor.
Cancer research Feb, 2012 | Pubmed ID: 22315351
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved